Chapman Steven Leonard sold $2.4M of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 5,694 shares of Natera, Inc. (NTRA) at an average of $418.25 ($406.00–$426.34, $2.38M total) across 2 trades over 2026-10-27 to 2026-10-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Oct 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

Insider sell of $2.38M by CEO may lead to short‑term price pressure.

02

Market read

The filing provides fresh insider activity data, relevant for traders monitoring biotech stocks.

03

What to watch

Potential upcoming clinical data releases that could offset sell‑side pressure.

Relevance 5/10Novelty 7/10Timing: post‑market filing

Background

Form 4 filing from SEC EDGAR discloses insider transactions.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

CEO Steven Leonard sold 5,694 shares for $2.38M via a 10b5‑1 plan, reducing his stake to 91,232 shares.

Expected impact

likely downward pressure as the market prices the insider sell

Evidence & confidence

A senior executive's sizable open‑market sale often triggers sell‑side sentiment, especially for a small‑cap biotech.

Market effects

May raise concerns for other biotech insiders and could affect sector sentiment.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

The sale could be routine under a pre‑arranged plan, not reflecting company fundamentals.

Key entities

  • Steven Leonard

    CEO and President of Natera, Inc.

  • Natera, Inc.

    Genomics testing company listed on NASDAQ.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.